Gyeonggi-do, South Korea

Jun Lee

This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Sk Biopharmaceuticals., Ltd.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jun Lee. Retrieved from https://idiyas.com/inventor/jun-lee-m3vb4h0n

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Jun Lee: Inventor in Pharmaceutical Research

Introduction

Jun Lee is an inventor based in Gyeonggi-do, South Korea. His work includes a patent concerning a compound designed to inhibit PRMT5, a target associated with certain diseases. Lee is affiliated with SK Biopharmaceuticals Co., Ltd.

Latest Patents

Lee is named on 1 patent, titled “Bicyclic Compound and Use Thereof.” The disclosure describes a compound derivative containing a 6-7 bicyclic ring and its potential use in preventing or treating diseases caused by PRMT5 through inhibition of the enzyme.

Career Highlights

Lee’s listed patent reflects research into medicinal compounds and potential therapeutic applications. The disclosed PRMT5-inhibiting activity is presented as a possible basis for developing treatments for diseases associated with this target.

Collaborations

Lee’s listed coworkers include Yong Je Shin and Jin Hee Kim. Their names appear alongside his in connection with the patent information provided.

Conclusion

Jun Lee’s patent work focuses on a bicyclic compound with potential therapeutic use as a PRMT5 inhibitor, highlighting his contribution to pharmaceutical research at SK Biopharmaceuticals Co., Ltd.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…